{
  "success": true,
  "pagesUsed": [
    0,
    1,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    20,
    21,
    22,
    23,
    24,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Upadacitinib",
        "type": {
          "id": "b4481f17-93a2-4ae9-8116-db0a03c77d79",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "b2a6a6e9-1455-4047-b8e6-431c40ea065f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Methotrexate (MTX)",
        "type": {
          "id": "5efb4840-4903-4987-8863-14a6c31bd692",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "70ec9b1f-f602-4ed7-bb1e-24a62b520a09",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Placebo for Upadacitinib",
        "type": {
          "id": "97db1b16-8799-4a24-9216-b3737f83776a",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "6c8b88ce-4461-4e85-81ec-9ff5eea1d7d7",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Placebo for MTX",
        "type": {
          "id": "4593cc9b-3c28-4a9d-9d1b-8530135a2cb3",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "4b95b776-e754-40ab-9ae4-a14e5d9e87bd",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for methotrexate to maintain blinding.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Folic acid",
        "type": {
          "id": "7c293d74-249b-4490-9755-fb596aa1a799",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "f39fdc72-f916-4865-a513-cb0eca9bdf7f",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "id": "int_6",
        "name": "Corticosteroids",
        "type": {
          "id": "b07ea50c-de67-49eb-83b7-901609f7e708",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "3fff1bbd-9220-4eab-955e-eb6ad10dba92",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "id": "int_7",
        "name": "NSAIDs",
        "type": {
          "id": "452a6661-9d96-4227-b644-5daf8e17b673",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "9951be5d-6018-4d64-80de-a3c9858479cd",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "id": "int_8",
        "name": "Acetaminophen",
        "type": {
          "id": "c04220de-ab3a-46a6-a9ae-14f4f214d48a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "3f1925d3-5a26-4f33-a337-75d0a79fd0cf",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for pain management."
      },
      {
        "id": "int_9",
        "name": "csDMARDs",
        "type": {
          "id": "9c932442-bb88-4243-863d-a33fad9fb7c4",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "692981bf-747f-4e28-a954-526761cc89ee",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "id": "int_10",
        "name": "Strong CYP3A inhibitors/inducers",
        "type": {
          "id": "0923b211-95bc-478a-b4a8-5893fe03204a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "eb14bfec-335c-41e1-bd09-f954096d6b23",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "id": "int_11",
        "name": "High-potency opiates",
        "type": {
          "id": "3f6452b1-a7f1-4197-bb14-ebc0668f384c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "95142bf2-c0c2-43d5-a7c8-de1c98134a9e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Upadacitinib tablet",
        "administrableDoseForm": {
          "id": "7be1f21c-84c3-4adf-842e-54ca54b5c3a3",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "80c03a3d-d0c3-43dc-a8b9-405b822458b3",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "ca24be83-f30d-4654-86ad-f77e256a39cb",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg, 30 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "AbbVie"
      },
      {
        "id": "prod_2",
        "name": "Methotrexate capsule",
        "administrableDoseForm": {
          "id": "a1d0e835-3601-47f6-9e72-00627d31ebe2",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "bd49d13f-d566-4363-983e-ed5021d1ba9d",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "dc4e532e-2aba-496a-be62-a807f2b1853d",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Upadacitinib 15 mg QD",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Up to 260 weeks"
      },
      {
        "id": "admin_2",
        "name": "Upadacitinib 30 mg QD",
        "instanceType": "Administration",
        "dose": "30 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "id": "admin_3",
        "name": "Methotrexate weekly",
        "instanceType": "Administration",
        "dose": "7.5 mg to 25 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "14 weeks (Period 1)"
      },
      {
        "id": "admin_4",
        "name": "Upadacitinib 15 mg Open-Label",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Upadacitinib",
        "instanceType": "Substance",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "id": "sub_2",
        "name": "Methotrexate",
        "instanceType": "Substance",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 11,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Upadacitinib",
        "role": "Investigational Product",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis."
      },
      {
        "name": "Methotrexate (MTX)",
        "role": "Comparator",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2."
      },
      {
        "name": "Placebo for Upadacitinib",
        "role": "Placebo",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding."
      },
      {
        "name": "Placebo for MTX",
        "role": "Placebo",
        "description": "Matching placebo capsules for methotrexate to maintain blinding."
      },
      {
        "name": "Folic acid",
        "role": "Background Therapy",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "name": "Corticosteroids",
        "role": "Concomitant Medication",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "name": "NSAIDs",
        "role": "Concomitant Medication",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "name": "Acetaminophen",
        "role": "Concomitant Medication",
        "description": "Permitted for pain management."
      },
      {
        "name": "csDMARDs",
        "role": "Rescue Medication",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "name": "Strong CYP3A inhibitors/inducers",
        "role": "Concomitant Medication",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "name": "High-potency opiates",
        "role": "Concomitant Medication",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "products": [
      {
        "name": "Upadacitinib tablet",
        "doseForm": "Tablet",
        "strength": "15 mg, 30 mg",
        "manufacturer": "AbbVie"
      },
      {
        "name": "Methotrexate capsule",
        "doseForm": "Capsule",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Upadacitinib",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "name": "Methotrexate",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "administrations": [
      {
        "name": "Upadacitinib 15 mg QD",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Up to 260 weeks"
      },
      {
        "name": "Upadacitinib 30 mg QD",
        "dose": "30 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "name": "Methotrexate weekly",
        "dose": "7.5 mg to 25 mg",
        "frequency": "once weekly",
        "route": "Oral",
        "duration": "14 weeks (Period 1)"
      },
      {
        "name": "Upadacitinib 15 mg Open-Label",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "devices": []
  }
}